MET and breast cancer: To assess the beneficial effects of TZD (we are using mostly the TZD rosiglitazone here) on platinum-based chemotherapies in mammary tumour models in vivo, we used either a MMTV-PyMT (“PyMT”) mouse model or an allograft of Met-1 cancer cells (originating from MMTV-PyMT mammary tumours) that we transplanted into isogenic wild-type mice.